​

Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TNDM Stock Forecast

Tandem Diabetes Care (TNDM) stock forecast, based on 39 Wall Street analysts, predicts a 12-month average price target of $30.50, with a high of $56.00 and a low of $21.00. This represents a 63.89% increase from the last price of $18.61.

$15 $24 $33 $42 $51 $60 High: $56 Avg: $30.5 Low: $21 Last Closed Price: $18.61

TNDM Stock Rating

Tandem Diabetes Care stock's rating consensus is Buy, based on 39 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (61.54%), 15 Hold (38.46%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 39 0 15 24 Strong Sell Sell Hold Buy Strong Buy

TNDM Price Target Upside V Benchmarks

TypeNameUpside
StockTandem Diabetes Care63.89%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks35.61%

Price Target Trends

1M3M12M
# Anlaysts-1020
Avg Price Target-$29.30$26.60
Last Closing Price$18.61$18.61$18.61
Upside/Downside-57.44%42.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 263911--23
Mar, 262814--24
Feb, 262713-123
Jan, 262713-123
Dec, 252614-123
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 23, 2026Truist Financial$27.00$24.579.89%45.08%
Feb 23, 2026Lake Street$50.00$24.57103.50%168.67%
Feb 23, 2026David RomanGoldman Sachs$28.00$24.5713.96%50.46%
Feb 23, 2026Matt MiksicBarclays$56.00$24.57127.92%200.91%
Feb 20, 2026Mizuho Securities$22.00$18.5218.79%18.22%
Feb 20, 2026Stifel Nicolaus$22.00$18.5218.79%18.22%
Feb 20, 2026UBS$22.00$18.5218.79%18.22%
Feb 20, 2026Matt O'BrienPiper Sandler$21.00$18.5213.39%12.84%
Feb 04, 2026Stifel Nicolaus$20.00$19.114.66%7.47%
Jan 09, 2026David RomanGoldman Sachs$25.00$22.5011.11%34.34%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 23, 2026Lake StreetHoldBuyupgrade
Feb 23, 2026Goldman SachsNeutralNeutralhold
Feb 23, 2026BarclaysOverweightOverweighthold
Feb 20, 2026UBSNeutralNeutralhold
Feb 20, 2026Bank of America SecuritiesNeutralupgrade
Feb 20, 2026Piper SandlerNeutralNeutralhold
Jan 09, 2026BernsteinMarket PerformMarket Performhold
Jan 09, 2026Goldman SachsNeutralNeutralhold
Dec 17, 2025RBC CapitalOutperformOutperformhold
Dec 11, 2025CitigroupNeutralNeutralhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.25$-1.47$-3.43$-1.47$-3.04---
Avg Forecast$0.30$-1.09$-3.21$-1.69$-1.22$-0.76$-0.27$-0.07
High Forecast$0.32$-1.07$-2.99$-1.35$-0.78$-0.19$0.34$-0.06
Low Forecast$0.30$-1.13$-3.39$-1.77$-1.43$-1.08$-0.66$-0.07
Surprise %-16.67%34.86%6.85%-13.02%149.18%---

Revenue Forecast

$650M $800M $950M $1B $1B $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$702.80M$801.22M$747.72M$940.20M$1.01B---
Avg Forecast$691.83M$802.00M$764.45M$909.25M$1.01B$1.13B$1.25B$1.37B
High Forecast$726.08M$823.70M$768.90M$935.20M$1.03B$1.13B$1.27B$1.40B
Low Forecast$678.59M$790.66M$755.55M$902.72M$999.97M$1.12B$1.23B$1.34B
Surprise %1.59%-0.10%-2.19%3.40%0.32%---

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$15.57M$-94.59M$-222.61M$-96.03M$-204.71M---
Avg Forecast$20.84M$21.80M$-222.61M$-101.26M$-78.17M$-44.51M$-14.71M$-4.22M
High Forecast$27.73M$29.60M$-135.07M$-87.83M$-50.98M$-12.35M$22.31M$-4.13M
Low Forecast$13.95M$13.99M$-310.15M$-114.70M$-92.69M$-70.45M$-43.04M$-4.35M
Surprise %-25.30%-533.97%--5.17%161.88%---

TNDM Forecast FAQ

Is Tandem Diabetes Care stock a buy?

Tandem Diabetes Care stock has a consensus rating of Buy, based on 39 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 15 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tandem Diabetes Care is a favorable investment for most analysts.

What is Tandem Diabetes Care's price target?

Tandem Diabetes Care's price target, set by 39 Wall Street analysts, averages $30.5 over the next 12 months. The price target range spans from $21 at the low end to $56 at the high end, suggesting a potential 63.89% change from the previous closing price of $18.61.

How does Tandem Diabetes Care stock forecast compare to its benchmarks?

Tandem Diabetes Care's stock forecast shows a 63.89% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (35.61%).

What is the breakdown of analyst ratings for Tandem Diabetes Care over the past three months?

  • April 2026: 13.04% Strong Buy, 39.13% Buy, 47.83% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 8.33% Strong Buy, 33.33% Buy, 58.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 8.70% Strong Buy, 30.43% Buy, 56.52% Hold, 0% Sell, 4.35% Strong Sell.

What is Tandem Diabetes Care’s EPS forecast?

Tandem Diabetes Care's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.76, marking a -75.00% decrease from the reported $-3.04 in 2025. Estimates for the following years are $-0.27 in 2027, and $-0.07 in 2028.

What is Tandem Diabetes Care’s revenue forecast?

Tandem Diabetes Care's average annual revenue forecast for its fiscal year ending in December 2026 is $1.13B, reflecting a 10.90% increase from the reported $1.01B in 2025. The forecast for 2027 is $1.25B, and $1.37B for 2028.

What is Tandem Diabetes Care’s net income forecast?

Tandem Diabetes Care's net income forecast for the fiscal year ending in December 2026 stands at $-44.508M, representing a -78.26% decrease from the reported $-205M in 2025. Projections indicate $-14.707M in 2027, and $-4.223M in 2028.